Acute kidney injury: clinicians confirm the “suPAR enemy” lies within

Up to 10% of patients who are hospitalized or undergo surgery will experience acute kidney injury (AKI), and as many as 50% of patients in intensive care units will meet the criteria for AKI, the National Kidney Foundation has determined. Some of these patients will progress to kidney failure within months. Physician-Scientists and other researchers at Rush University Medical Center, in collaboration with colleagues at other institutions, have revealed a new treatment target that may help change the outcome for patients at risk of AKI. The results were published in Jan. 29 in The New England Journal of Medicine. In this study, the team led by Dr. Jochen Reiser, MD, PhD, professor at Rush University Medical Center and chairperson of Rush’s Department of Internal Medicine, found evidence that a specific protein produced by immune cells in the bone marrow, called soluble urokinase plasminogen activator receptor (suPAR,) is a strong risk factor for acute forms of kidney failure, that occur as consequence of general medical procedures. suPAR has been repeatedly shown to harm kidneys. Chronically elevated blood levels are linked to development of Chronic Kidney Disease (CKD), a paper published by Reiser and colleagues in The New England Journal of Medicine in 2015.

Now, the new paper is showing that having elevated suPAR levels is also a risk factor for acute kidney inury – a sudden decline in kidney function that can be a severe side effect of general medical procedures. Reiser believes that high suPAR levels will inform physician-patient conversations about preventing kidney disease, just as high cholesterol levels signal the need for lifestyle changes and protective drugs, such as statins, to avert heart attacks and strokes. Dr. Reiser is being clear: “Nephrology has found its global risk molecule: suPAR. Any kidney disease, chronic or acute, genetic or acquired, is better off with a lower suPAR level. By looking at suPAR levels in patients, we can possibly prevent damage to healthy kidneys that is often irreversible.” This is why he and colleagues performed a two-pronged investigation of suPAR. First, they looked at suPAR levels and the risk of acute kidney injury in three clinical settings. They collected blood samples from patients about to undergo coronary angiography for suspected heart disease, patients undergoing cardiac surgery, and critically ill patients who had been admitted to the intensive care unit. The team found that suPAR levels independently predicted risk of AKI in each of these clinical settings.

If a person had higher suPAR levels before undergoing coronary angiography or cardiac surgery, or upon admission to the intensive care unit, they were at much greater risk of developing AKI afterwards. These associations were entirely independent of other clinical characteristics, such as age, gender, race, severity of illness, and baseline kidney function. The team divided patients into quartiles based on how high their suPAR levels were and compared outcomes for patients across quartiles. They found that risk of AKI increased steadily with increasing suPAR levels, with an increase of 3.5 to four times the risk of AKI for those in the highest quartile compared to the lowest. High SuPAR levels consistently predicted AKI in these patients, with levels above 3 nanograms per milliliter doubling the risk of AKI. In total, the study included 4,769 patients. These findings led the researchers to the second phase of the study. They employed mouse models of acute kidney injury to investigate whether high suPAR is actually a contributing cause of the complication. When the mice were exposed to contrast used in patients undergoing coronary angiography, the researchers found that higher levels of suPAR led to worsening of kidneys compared to mice with normal levels.

However, when mice were pretreated with a monoclonal antibody to block suPAR, the researchers managed to reduce the development and the severity of kidney injury. While the team is looking at utilizing treatments and medications already used for other purposes, like statins or immune modulators, they have also sparked the creation of novel humanized suPAR antibodies that once fully developed will be explored in clinical trials.

  • Edited by Dr. Gianfrancesco Cormaci, PhD, specialist in Clinical Biochemistry.

Scientific references

Hayek S et al., Reiser J. N Engl J Med. 2020 Jan 30; 382(5):416-26. 

Hall A et al., Ostermann M. BMC Nephrol. 2018 Aug 2; 19(1):191. 

Loosen SH, Tacke F et al. Oncotarget. 2018 Jun; 9(43):27027-38.

Informazioni su Dott. Gianfrancesco Cormaci 1971 Articoli
- Laurea in Medicina e Chirurgia nel 1998 (MD Degree in 1998) - Specialista in Biochimica Clinica nel 2002 (Clinical Biochemistry specialty in 2002) - Dottorato in Neurobiologia nel 2006 (Neurobiology PhD in 2006) - Ha soggiornato negli Stati Uniti, Baltimora (MD) come ricercatore alle dipendenze del National Institute on Drug Abuse (NIDA/NIH) e poi alla Johns Hopkins University, dal 2004 al 2008. - Dal 2009 si occupa di Medicina personalizzata. - Detentore di un brevetto sulla preparazione di prodotti gluten-free a partire da regolare farina di frumento immunologicamente neutralizzata (owner of a patent concerning the production of bakery gluten-free products, starting from regular wheat flour). - Autore di un libro riguardante la salute e l'alimentazione, con approfondimenti su come questa condizioni tutti i sistemi corporei. - Autore di articoli su informazione medica, salute e benessere sui siti web salutesicilia.com e medicomunicare.it